Business
Annual Report 2018 and Notice of AGM
Annual Report 2018 and Notice of AGM.
About this update from Steppe Cement Ltd
[{"type":"text","content":"\n \nRNS Number : 9335Y Steppe Cement Limited 15 May 2019 \n\n15 May 2019\n \nSteppe Cement Ltd\nAnnual Report 2018 and Notice of Annual General Meeting\n \nSteppe Cement Ltd wishes to inform that its Annual General Meeting will be held at Suite 10.1, 10th Floor, West Wing, Rohas Perkasa, 8 Jalan Perak, Kuala Lumpur, Malaysia on Wednesday, 12 June 2019 at 2:30 p.m.\n \nThe resolutions for the meeting will be:\n \nResolution 1\nAdoption of Audited Financial Statements\n \nTo receive and adopt the audited financial statements for year ended 31 December 2018.\n \nResolution 2\nFirst and Final Tax Exempt Dividend for the Financial Year ended 31 December 2018\n \nTo approve the payment of First and Final Tax Exempt Dividend of GBP0.03 per ordinary share of no par value each in respect of the financial year ended 31 December 2018.\n \nResolution 3\nRe-election of Directors\n \n To re-elect the following directors who offered themselves for re-election:\n \n3.1 Xavier Blutel\n3.2 Javier del Ser Perez\n3.3 Rupert Wood\n \nResolution 4\nChange of Auditors\n \nTo approve and ratify the change of Auditors from Messrs. Deloitte & Touche PLT to Messrs. Deloitte PLT, due to change of name, approved by the Board of Directors on 26 November 2018.\n \n \nThe Annual Report 2018 will be posted on Monday, 20 May 2019, to shareholders who have elected to receive a physical copy.\n \nA copy of the Annual Report 2018 and the Notice of Annual General Meeting is available on the website at www.steppecement.com. \n \n \nSteppe Cement's AIM nominated adviser and broker is RFC Ambrian Limited.\n \nNominated Adviser contact: Stephen Allen or Andrew Thomson at +61 8 9480 2500.\n \nBroker contact: Charlie Cryer at +44 20 3440 6800.\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END NOASFISLLFUSEDI\n ","length":4492,"tagName":"div"}]